leflunomide has been researched along with Atherogenesis in 2 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tecer, D | 1 |
| Sunar, I | 1 |
| Ozdemirel, AE | 1 |
| Tural, R | 1 |
| Kucuksahin, O | 1 |
| Sepici Dincel, A | 1 |
| Ataman, S | 1 |
| Minoretti, P | 1 |
| Bruno, A | 1 |
| Di Vito, C | 1 |
| Emanuele, E | 1 |
2 other studies available for leflunomide and Atherogenesis
| Article | Year |
|---|---|
Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Atherosclerosis | 2019 |
Leflunomide as an antiatherogenic drug.
Topics: Antigen-Presenting Cells; Antirheumatic Agents; Atherosclerosis; Chemotaxis; Dendritic Cells; Humans | 2007 |